Toll-Like Receptor Agonists as Adjuvants for Allergen Immunotherapy.

Front Immunol · 2020 · PMC7688745 · PMID 33281825

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In a small phase I/IIa RDBPCT, a sublingual combination of allergen and MPL showed a trend for a reduction in the proportion of positive nasal challenge tests and reduced IgE and enhanced IgG compared to grass pollen sublingual immunotherapy alone ( 94 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.